default author photo

Manuel Ruiz Borrego

Hospital Universitario Virgen del Rocío - Medical Oncology Department

Seville

Spain

  • Hospital Universitario Virgen del Rocío - Medical Oncology Department

SCHOLARLY PAPERS

2

DOWNLOADS

172

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Prevention of Sacituzumab Govitecan-Related Neutropenia and Diarrhea in Patients with Her2-Negative Advanced Breast Cancer (PRIMED): An Open-Label, Single-Arm, Phase 2 Trial

Number of pages: 21 Posted: 17 Mar 2025
José Manuel Pérez-García, Maria Gion, Manuel Ruiz Borrego, Isabel Blancas, Elena López-Miranda, Salvador Blanch, Sabela Recalde, Cristina Reboredo Rendo, Xavier González, Nerea Ancizar, Serafin Morales, Patricia Cortez, Zuzanna Piwowarska, Eileen Shimizu, José Antonio Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez-Bueno, Javier Cortés and Antonio Llombart-Cussac
Quiron Group - International Breast Cancer Center (IBCC), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Virgen del Rocío - Medical Oncology Department, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Complex Hospitalari Universitari Moisès Broggi, Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña, Hospital Universitario General de Catalunya, Hospital Universitario Donostia, Hospital Universitari Arnau de Vilanova, Hospital Beata Maria Ana de Jesus, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Dexeus, Vall d'Hebron Institute of Oncology and Medica Scientia Innovation Research (MEDSIR)
Downloads 96 (709,832)

Abstract:

Loading...

Sacituzumab govitecan, triple-negative, hormone receptor-positive/HER2-negative, neutropenia, diarrhea, advanced breast cancer, loperamide, granulocyte-colony stimulating factor, G-CSF.

2.

Chemotherapy De-Escalation Using an 18F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial

Number of pages: 38 Posted: 02 Dec 2020
José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begoña Bermejo, Peter Schmid, Frederik Marmé, Santiago Escrivá de-Romani, Lourdes Calvo, Nuria Ribelles, Noelia Martinez, Cinta Albacar, Aleix Prat, Florence Dalenc, Kerrou Khaldoun, Marco Colleoni, Noemi Afonso, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac and PHERGain Steering Committee and Trial Investigators
Quiron Group - International Breast Cancer Center (IBCC), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Hospital Universitario Virgen del Rocío - Medical Oncology Department, Institut Català d'Oncologia, Hospital Clínico Universitario de Valencia, Queen Mary University of London - Barts ECMC, Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Vall d'Hebron University Hospital - Breast Cancer Group, Hospital Universitario A Coruña - UGC Oncología Intercentros, Hospital Universitario Virgen de la Victoria, Universidad de Alcalá, IRYCIS, Hospital Universitari Sant Joan de Reus - Department of Medical Oncology, Hospital Clinic of Barcelona - Department of Medical Oncology, Institut Claudius Regaud - IUCT-Oncopole, CRCT, Inserm, Sorbonne University - Tenon Hospital, Nuclear Medicine and PET Center Department, European Institute of Oncology (IEO) - Division of Medical Senology, Universidade do Porto - Centro Hospitalar, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Vall d'Hebron Institute of Oncology, Universidad Catolica - Hospital Arnau de Vilanova and Independent
Downloads 76 (830,555)

Abstract:

Loading...

Trastuzumab; Pertuzumab; De-escalation; Pathologic complete response; FDG-PET/CT; HER2-positive; Early breast cancer